{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:00:31Z","timestamp":1780441231284,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jiac.2017.03.004","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T20:49:56Z","timestamp":1491338996000},"page":"374-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bactericidal activity and post-antibiotic effect of ozenoxacin against Propionibacterium acnes"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4777-6039","authenticated-orcid":false,"given":"Shoji","family":"Kanayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuko","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsumi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomasa","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2017.03.004_bib1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(11)60321-8","article-title":"Acne vulgaris","volume":"379","author":"Williams","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2017.03.004_bib2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaad.2006.08.048","article-title":"Guidelines of care for acne vulgaris management","volume":"56","author":"Strauss","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jiac.2017.03.004_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaad.2009.01.019","article-title":"New insights into the management of acne: an update from the global alliance to improve outcomes in acne group","volume":"60","author":"Thiboutot","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jiac.2017.03.004_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04374.x","article-title":"European evidence-based (S3) guidelines for the treatment of acne","volume":"26","author":"Nast","year":"2012","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jiac.2017.03.004_bib5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/jid.2013.505","article-title":"New insights into acne pathogenesis: Propionibacterium acnes activates the inflammasome","volume":"134","author":"Contassot","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jiac.2017.03.004_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/jdv.12224","article-title":"Propionibacterium acnes: an update on its role in the pathogenesis of acne","volume":"28","author":"Beylot","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jiac.2017.03.004_bib7","first-page":"155","article-title":"A\u00a0comparative phase III study of ozenoxacin lotion in patients with acne vulgaris","volume":"31","author":"Kawashima","year":"2015","journal-title":"J\u00a0Clin Ther Med"},{"key":"10.1016\/j.jiac.2017.03.004_bib8","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1099\/jmm.0.067611-0","article-title":"Relationship between the severity of acne vulgaris and antimicrobial resistance of bacteria isolated from acne lesions in a hospital in Japan","volume":"63","author":"Nakase","year":"2014","journal-title":"J\u00a0Med Microbiol"},{"key":"10.1016\/j.jiac.2017.03.004_bib9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1346-8138.2011.01423.x","article-title":"First report of high levels of clindamycin-resistant Propionibacterium acnes carrying erm(X) in Japanese patients with acne vulgaris","volume":"39","author":"Nakase","year":"2012","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jiac.2017.03.004_bib10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1046\/j.1365-2133.2003.05067.x","article-title":"Antibiotic-resistant acne: lessons from Europe","volume":"148","author":"Ross","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jiac.2017.03.004_bib11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1346-8138.2000.tb02174.x","article-title":"The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions","volume":"27","author":"Nishijima","year":"2000","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jiac.2017.03.004_bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.diagmicrobio.2013.11.010","article-title":"Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values","volume":"78","author":"Tato","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2017.03.004_bib13","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1128\/AAC.01509-13","article-title":"In\u00a0vitro activity of ozenoxacin against quinolone-susceptible and quinolone-resistant Gram-positive bacteria","volume":"57","author":"L\u00f3pez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.03.004_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jac\/dku375","article-title":"In\u00a0vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci","volume":"70","author":"L\u00f3pez","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.03.004_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/jac\/49.3.455","article-title":"In\u00a0vitro and in\u00a0vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone","volume":"49","author":"Yamakawa","year":"2002","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.03.004_bib16","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jiac.2016.03.006","article-title":"In\u00a0vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S.\u00a0aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan","volume":"22","author":"Kanayama","year":"2016","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2017.03.004_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1099\/jmm.0.000293","article-title":"Antimicrobial activities of ozenoxacin against the isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris","volume":"65","author":"Nakajima","year":"2016","journal-title":"J\u00a0Med Microbiol"},{"key":"10.1016\/j.jiac.2017.03.004_bib18","first-page":"279","article-title":"An open label, phase III study of ozenoxacin lotion in patients with superficial infection of the skin","volume":"31","author":"Kawashima","year":"2015","journal-title":"J\u00a0Clin Ther Med"},{"key":"10.1016\/j.jiac.2017.03.004_bib19","first-page":"1045","article-title":"Guidelines for the treatment of acne vulgaris 2016","volume":"126","author":"Hayashi","year":"2016","journal-title":"Jpn J Dermatol"},{"key":"10.1016\/j.jiac.2017.03.004_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.03.004_bib21","series-title":"Antibiotics in laboratory medicine","first-page":"296","article-title":"Postantibiotic effect","author":"Craig","year":"1996"},{"key":"10.1016\/j.jiac.2017.03.004_bib22","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1128\/AAC.47.12.3935-3941.2003","article-title":"Pharmacodynamics of the new des-F(6)-quinolone garenoxacin in a murine thigh infection model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.03.004_bib23","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1128\/AAC.46.6.1665-1670.2002","article-title":"Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models","volume":"46","author":"Andes","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.03.004_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1472-765X.2011.03090.x","article-title":"Norfloxacin and ursolic acid: in\u00a0vitro association and postantibiotic effect against Staphylococcus aureus","volume":"53","author":"Filocamo","year":"2011","journal-title":"Lett Appl Microbiol"},{"key":"10.1016\/j.jiac.2017.03.004_bib25","series-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.jiac.2017.03.004_bib26","series-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2014"},{"key":"10.1016\/j.jiac.2017.03.004_bib27","article-title":"Antimicrobial susceptibility testing","volume":"vol. 2","author":"Hindler","year":"2010"},{"key":"10.1016\/j.jiac.2017.03.004_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.anaerobe.2016.10.012","article-title":"Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase IV","volume":"42","author":"Nakase","year":"2016","journal-title":"Anaerobe"},{"key":"10.1016\/j.jiac.2017.03.004_bib29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000098427","article-title":"Molecular characterization of 8-methoxyfluoroquinolone resistance in a clinical isolate of methicillin-resistant Staphylococcus aureus","volume":"53","author":"Horii","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jiac.2017.03.004_bib30","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1128\/AAC.39.7.1554","article-title":"Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus","volume":"39","author":"Ferrero","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.03.004_bib31","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of quinolone action and resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.jiac.2017.03.004_bib32","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1128\/AAC.47.4.1399-1402.2003","article-title":"Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents","volume":"47","author":"Credito","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.03.004_bib33","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1128\/AAC.43.10.2547","article-title":"Bactericidal activity and postantibiotic effect of levofloxacin against anerobes","volume":"43","author":"Pendland","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.03.004_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/40.1.39","article-title":"Correlation between bactericidal activity and postantibiotic effect for five antibiotics with different mechanisms of action","volume":"40","author":"Li","year":"1997","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.03.004_bib35","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1093\/nar\/gkt124","article-title":"Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance","volume":"41","author":"Aldred","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jiac.2017.03.004_bib36","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1128\/AAC.00316-15","article-title":"Differences in antibiotic-induced oxidative stress responses between laboratory and clinical isolates of Streptococcus pneumoniae","volume":"59","author":"Dridi","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X1730051X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X1730051X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:56:11Z","timestamp":1761159371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X1730051X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1341321X1730051X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2017.03.004","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bactericidal activity and post-antibiotic effect of ozenoxacin against Propionibacterium acnes","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2017.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}